When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALT - Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Altimmune Inc.
2024-03-18 10:00:07 ET
Summary
Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda.
Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competitive market landscape, potentially outperforming Wegovy in efficacy.
The race to redefine obesity treatment is heating up, with several other pharmaceutical companies developing GLP-1 agonists and exploring alternative targets.
The Evolution of Obesity Pharmacotherapy: From Phentermine to Wegovy